Locoregional recurrence in patients with HER2 positive breast cancer

Janaina Brollo, Maximiliano Cassilha Kneubil, Edoardo Botteri, Nicole Rotmensz, Bruno Achutti Duso, Luca Fumagalli, Marzia Adelia Locatelli, Carmen Criscitiello, Visnu Lohsiriwat, Aron Goldhirsch, Maria Cristina Leonardi, Roberto Orecchia, Giuseppe Curigliano

Résultats de recherche: Contribution à un journalArticleRevue par des pairs

13 Citations (Scopus)

Résumé

Literature shows that HER2/neu positive breast cancer cells are more sensitive to radiation-induced apoptosis by targeting the epidermal growth factor receptor family tyrosine kinase. We selected 466 patients with pT1-2 HER2/neu positive tumors who received adjuvant trastuzumab for primary invasive breast cancer. Patients were divided into three groups [Quadrantectomy followed by conventional radiotherapy vsQuadrantectomy followed by Intra-operative radiotherapy with electrons vsMastectomy without radiotherapy]. After a median follow-up of 52 months, the 5-year cumulative incidence of locoregional recurrence (LRR) was 1.9%, 11.5% and 5.0% respectively ( p<0.01). At the multivariate analysis, extensive perivascular invasion, Luminal B HER2/Progesterone Receptor (PgR) negative status and Quadrantectomy followed by Intra-operative radiotherapy with electrons have significantly increased the risk of LRR. Our results suggest that HER2/neu positive breast cancer might have better outcomes when treated simultaneously with external radiotherapy and trastuzumab. Moreover, we underline the importance of PgR and further new stratification of risk among luminal subtypes.

langue originaleAnglais
Pages (de - à)856-862
Nombre de pages7
journalBreast
Volume22
Numéro de publication5
Les DOIs
étatPublié - 1 janv. 2013
Modification externeOui

Contient cette citation